Table 4.
Risk of NAFLD in Participants without Transitions between Obesity Status from Baseline to Follow-up According to the Variability of Body Weight
| Presence of NAFLD | Model 1 | Model 2 | Model 3 | |
|---|---|---|---|---|
| Non-obese to non-obese, low ASVW | 547 (8.1) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Non-obese to non-obese, high ASVW | 637 (11.7) | 1.42 (1.25–1.60) | 1.39 (1.23–1.58) | 1.39 (1.22–1.57) |
| Obese to obese, low ASVWa | 200 (41.8) | 5.21 (4.23–6.42) | 4.20 (3.39–5.21) | 3.76 (3.02–4.67) |
| Obese to obese, high ASVW | 457 (43.7) | 6.66 (5.70–7.78) | 5.43 (4.62–6.39) | 4.85 (4.11–5.72) |
| Non-obese to non-obese, low CV | 559 (8.6) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Non-obese to non-obese, high CV | 625 (10.9) | 1.54 (1.36–1.75) | 1.58 (1.39–1.79) | 1.58 (1.39–1.80) |
| Obese to obese, low CVa | 296 (39.1) | 4.50 (3.78–5.36) | 3.68 (3.07–4.41) | 3.30 (2.74–3.96) |
| Obese to obese, high CV | 361 (47.1) | 8.79 (7.4–10.46) | 7.32 (6.13–8.76) | 6.52 (5.44–7.82) |
Values are expressed as number (%) or odds ratio (95% confidence interval). Model 1: Adjusted for age and sex; Model 2: Adjusted for Model 1+fasting blood glucose, systolic blood pressure, triglyceride, low-density lipoprotein cholesterol, smoking status, exercise, and alcohol intake; Model 3: Adjusted for Model 2+homeostatic model assessment of insulin resistance, glycated hemoglobin, aspartate transaminase.
NAFLD, nonalcoholic fatty liver disease; ASVW, average successive variability of weight; CV, coefficient of variation.
Body mass index cut off of 25 kg/m2 was used to define obesity in the Korean population in this study.